We are live on ! Find out more
Squarepoint

Squarepoint Portfolio holdings

AUM $85.1B
1-Year Est. Return 20.93%
This Fund
S&P 500
This Quarter Est. Return
+1.61%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$94B
AUM Growth
-$5.55B
Cap. Flow
-$6.11B
Cap. Flow %
-6.5%
Top 10 Hldgs %
18.25%
Holding
5,056
New
758
Increased
1,544
Reduced
1,769
Closed
869

Top Buys

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$1.52B
2
AVGO icon
Broadcom
AVGO
+$409M
3
NOW icon
ServiceNow
NOW
+$359M
4
TSLA icon
Tesla
TSLA
+$230M
5
TMUS icon
T-Mobile US
TMUS
+$219M

Sector Composition

Rank Sector Weight
1 Technology 11.46%
2 Consumer Discretionary 6.93%
3 Industrials 5.09%
4 Financials 5.05%
5 Healthcare 4.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LAES icon
4076
SEALSQ Corp
LAES
$541M
$71.5K ﹤0.01%
18,917
-151,307
-89% -$771K
GTN icon
4077
Gray Television
GTN
$407M
$71.5K ﹤0.01%
+14,770
New +$72.3K
RRGB icon
4078
Red Robin
RRGB
$134M
$71K ﹤0.01%
+17,531
New +$88K
CNDT icon
4079
Conduent
CNDT
$230M
$70.8K ﹤0.01%
36,865
+693
+2% +$1.52K
ANTX icon
4080
AN2 Therapeutics
ANTX
$177M
$70.2K ﹤0.01%
61,612
-2,655
-4% -$3.1K
ABAT icon
4081
American Battery Technology Co
ABAT
$301M
$70.1K ﹤0.01%
+20,992
New +$98.3K
JBLU icon
4082
CALL
JetBlue
JBLU
$1.96B
$70.1K ﹤0.01%
15,400
+4,600
+43% +$21K
LXRX icon
4083
Lexicon Pharmaceuticals
LXRX
$1.02B
$69.5K ﹤0.01%
60,472
+1,796
+3% +$2.47K
ACB
4084
Aurora Cannabis
ACB
$165M
$69.2K ﹤0.01%
+16,398
New +$80.2K
YSG
4085
Yatsen Holding
YSG
$311M
$69.1K ﹤0.01%
+17,752
New +$113K
AMC icon
4086
CALL
AMC Entertainment Holdings
AMC
$2.03B
$69K ﹤0.01%
44,200
AVIR icon
4087
Atea Pharmaceuticals
AVIR
$379M
$68.9K ﹤0.01%
+19,311
New +$61.4K
PNNT
4088
Pennant Park Investment Corp
PNNT
$215M
$68.7K ﹤0.01%
+11,525
New +$72K
FUBO icon
4089
PUT
FuboTV Inc
FUBO
$245M
$68.5K ﹤0.01%
2,267
+292
+15% +$11.7K
GALT icon
4090
Galectin Therapeutics
GALT
$229M
$68.5K ﹤0.01%
+16,462
New +$86.7K
IOVA icon
4091
Iovance Biotherapeutics
IOVA
$2.23B
$68.3K ﹤0.01%
25,001
-18,757
-43% -$43.4K
TARA icon
4092
Protara Therapeutics
TARA
$226M
$67.6K ﹤0.01%
12,692
+307
+2% +$1.71K
SFIX
4093
PUT
Stitch Fix
SFIX
$478M
$64.6K ﹤0.01%
12,300
SMRT icon
4094
SmartRent
SMRT
$183M
$64.2K ﹤0.01%
31,774
+16,734
+111% +$27.4K
OVID icon
4095
Ovid Therapeutics
OVID
$435M
$63.6K ﹤0.01%
39,034
-75,889
-66% -$117K
TKC icon
4096
Turkcell
TKC
$4.84B
$63.5K ﹤0.01%
+11,601
New +$67.7K
ACRV icon
4097
Acrivon Therapeutics
ACRV
$68.5M
$63K ﹤0.01%
26,162
-78,162
-75% -$170K
DNN icon
4098
CALL
Denison Mines
DNN
$2.63B
$60.1K ﹤0.01%
22,600
UGP icon
4099
Ultrapar
UGP
$6.87B
$59.2K ﹤0.01%
15,696
-26,332
-63% -$104K
SVCO
4100
Silvaco Group
SVCO
$260M
$57.5K ﹤0.01%
+14,196
New +$70.5K

Similar funds

Squarepoint's Q4 2025 Portfolio in Review

As of Q4 2025, Squarepoint held 5,056 positions worth $94B, down 5.6% from $99.5B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Squarepoint withdrew a net $6.11B in Q4 2025, closing 869 positions and reducing 1,769 holdings. Its most notable exit was State Street Communication Services Select Sector SPDR ETF, an estimated $328M position sold in full.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Squarepoint opened a new position in Medline Inc worth $79.8M.

  • Squarepoint's largest Q4 2025 buy was Medline Inc: 1,900,000 shares worth $79.8M.
  • Squarepoint added most to iShares Core S&P 500 ETF in Q4 2025, an estimated $1.52B increase.
  • Squarepoint's biggest Q4 2025 reduction was Walmart Inc, cutting an estimated $253M.
  • Squarepoint fully exited State Street Communication Services Select Sector SPDR ETF in Q4 2025, selling an estimated $328M.
  • Squarepoint's ten largest holdings make up 18% of its $94B portfolio in Q4 2025.
  • Squarepoint opened 758 new positions and closed 869 in Q4 2025.
  • Squarepoint's portfolio value fell 5.6% quarter-over-quarter to $94B.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.